遗传性出血性毛细血管扩张症 中国就医指南

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare, autosomal dominant genetic disorder characterized by abnormal blood vessel formation—specifically, direct connections between arteries and veins without intervening capillaries (arteriovenous malformations, or AVMs) and fragile, dilated small vessels (telangiectasias). These vascular anomalies occur predominantly in the skin, mucosa (especially nasal and oral), lungs, brain, liver, and gastrointestinal tract. Pathogenesis stems from mutations in genes involved in transforming growth factor-beta (TGF-β) signaling, most commonly ENG (encoding endoglin, HHT type 1), ACVRL1 (encoding ALK1, HHT type 2), and less frequently SMAD4 (HHT–juvenile polyposis overlap syndrome) or GDF2. Dysfunctional TGF-β signaling impairs endothelial cell maturation and vascular stabilization, leading to progressive telangiectasia development and AVM formation. Epidemiologically, HHT affects approximately 1 in 5,000 to 1 in 8,000 individuals worldwide, with no significant gender or ethnic predilection; however, underdiagnosis remains widespread—up to 80% of cases may go unrecognized due to variable expressivity and mild early presentations. Key risk factors include family history (nearly 100% penetrance by age 40), consanguinity (rarely), and specific genotype–phenotype correlations: ENG mutations confer higher risk of pulmonary AVMs (20–30%), while ACVRL1 mutations correlate with hepatic AVMs (70–80%) and lower pulmonary involvement. Clinical manifestations range from recurrent spontaneous epistaxis (present in >90% of adults), which often begins in childhood or adolescence, to life-threatening complications including ischemic stroke (from paradoxical embolism via pulmonary AVMs), cerebral hemorrhage (from cerebral AVMs), high-output heart failure (due to hepatic shunting), and severe iron-deficiency anemia from chronic GI bleeding. Quality of life is significantly impaired: patients report chronic fatigue, social embarrassment from visible telangiectasias and nosebleeds, anxiety about sudden hemorrhage or stroke, limitations in physical activity, frequent medical visits, and reduced work productivity. Psychological burden—including depression and health-related anxiety—is prevalent, particularly among those with untreated pulmonary or cerebral AVMs. Early diagnosis using the Curaçao criteria (spontaneous recurrent epistaxis, multiple mucocutaneous telangiectasias, visceral AVMs, and first-degree family history) enables timely screening (e.g., contrast echocardiography for pulmonary AVMs, brain MRI, hepatic Doppler) and preventive interventions, substantially reducing morbidity and mortality.

# 遗传性出血性毛细血管扩张症（HHT）治疗方案与费用明细（血液科）

一、非手术/保守治疗

适用人群：轻中度鼻出血、皮肤黏膜毛细血管扩张、无严重内脏动静脉畸形（AVM）者。

• •铁剂补充+静脉补铁（缺铁性贫血）：口服硫酸亚铁片（30–60元/盒），静脉蔗糖铁注射（1200–2800元/疗程，含血清铁、铁蛋白、TSAT检测费320元）
• •抗纤溶药物（氨甲环酸）：口服片剂（85–150元/月），含凝血功能+肝肾功能监测（260元/次）
• •鼻腔局部治疗（激光/电凝前准备）：鼻内镜检查+生理盐水冲洗指导（180元/次）

二、微创介入治疗

适用人群：反复鼻出血伴鼻腔毛细血管丛扩张（经鼻内镜证实）、肺/肝AVM高危者。

• •鼻腔激光/射频消融术（单侧/双侧分次）：4800–9600元/次（含术前鼻窦CT 320元、凝血四项120元）
• •肺AVM栓塞术（数字减影血管造影DSA引导）：3.2–6.8万元/病灶（含术前HRCT 580元、肺功能+血气分析420元）

三、特殊复杂/并发症方案

适用人群：脑AVM破裂、胃肠道大出血、重度肝AVM致高输出性心衰。

• •多学科联合栓塞+靶向药物（贝伐珠单抗）：首周期12.6–18.5万元（含基因检测7200元、VEGF水平监测360元、住院监护费日均850元）

方案快速选择指南

• •预算＜5000元/年：首选口服铁剂+氨甲环酸+定期随访；
• •反复鼻出血影响生活：推荐单侧鼻腔射频消融（约6000元）；
• •确诊肺AVM或消化道出血：必须行DSA评估，优先介入栓塞；
• •合并多系统AVM或HHT2型突变：转血液科-影像科-呼吸科MDT，启动贝伐珠单抗治疗。